Evidence map›Paper›PMID 30349972›Full record

ReviewWiener medizinische Wochenschrift (1946)2019

[The role of molecular imaging (PET-CT) in the diagnostic and treatment pf prostate cancer].

Siroos Mirzaei, Peter Knoll, Shahin Zandieh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Wiener medizinische Wochenschrift (1946), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Siroos MirzaeiInstitut für Nuklearmedizin mit PET-Zentrum, Wilhelminenspital, Montleartstraße 37, 1160, Wien, Österreich. siroos.mirzaei@wienkav.at.
Peter KnollInstitut für Nuklearmedizin mit PET-Zentrum, Wilhelminenspital, Montleartstraße 37, 1160, Wien, Österreich.
Shahin ZandiehInstitut für Radiologie und Nuklearmedizin, Hanusch-Krankenhaus, Wien, Österreich.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is the most frequent cancer type in men in industrialized countries. In case of biochemical recurrent disease of prostate cancer is molecular imaging with PET-CT or PET-MRI a very promising modality for the detection of local recurrence, lymph node involvement or distant metastasis. Of the so far implemented radiopharmaceuticals the radioactive labeled PSMA ligands (i. e. Ga-68 PSMA) have prevailed. There are also in the meanwhile treatment approaches with PSMA ligands (i. e. Lu-177 PSMA) in case of metastatic disease.

Indexed as

Molecular ImagingProstatic NeoplasmsEdetic AcidGallium RadioisotopesHumansMagnetic Resonance ImagingMaleMultimodal ImagingNeoplasm Recurrence, LocalOligopeptidesPositron Emission Tomography Computed TomographyRadiopharmaceuticalsEdetic AcidGallium-68Gallium RadioisotopesOligopeptidesRadiopharmaceuticalsPETProstate cancerPSMA

Identifiers

PMID30349972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.